Elevated expression of TLR2 and its correlation with disease activity and clinical manifestations in adult-onset Still’s disease

Jae Ho Han1,3, Mi-Hyun Ahn2,3, Ju-Yang Jung3, Ji-Won Kim2, Chang-Hee Suh2, Ji Eun Kwon1, Hyunee Yim1 & Hyoun-Ah Kim2*

This study investigated the role of Toll-like receptor 1 (TLR1), TLR2, TLR4, TLR7, and TLR9 in patients with adult-onset Still’s disease (AOSD). This study included 20 patients with AOSD and 15 healthy controls (HCs). TLR expression in the peripheral blood was quantified using flow cytometry; TLR expression pattern, in the skin lesions and lymph nodes (LNs) of patients with AOSD, was evaluated immunohistochemically. Significantly higher mean intensities of cells presenting TLR2 and TLR7 from whole blood were observed in patients with AOSD than in HCs. TLR2 expression in whole cells correlated with systemic scores, levels of lactate dehydrogenase and ferritin and serum levels of interleukin-1β (IL-1β), IL-6, and IL-18. The percentage of TLR2-positive inflammatory cells was higher in skin biopsy samples from patients with AOSD than those in HCs. TLR9-expressing positive inflammatory cell counts were higher in skin lesions from patients with AOSD than those in the HC, eczema, and psoriasis groups. The expression levels of TLR1, TLR4, TLR7, and TLR9 were higher in LNs of patients with AOSD than in those with T cell lymphoma and reactive lymphadenopathy. Circulating TLR2- and TLR7-positive cells may contribute to the pathogenesis of AOSD. Furthermore, immunohistochemical staining for TLRs in skin lesions and LNs may aid in differentiating AOSD from similar conditions.

Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder characterized by spiking fever, evanescent skin rashes during fever, multiple arthralgia, organomegaly, and serositis. Although the aetiology of AOSD is still inconclusive, several factors, such as genetic background, viral or bacterial infections, and aberrant immune response are involved. AOSD inflammation is triggered by the activation of the innate immune system along with aberrant production of proinflammatory cytokines, such as interleukin (IL)-1β, tumour necrosis factor-α (TNF-α), and IL-18.

Some clinical manifestations of AOSD, such as spiking fever, lymphadenitis, and liver enzyme elevation, are similar to those of viral or bacterial infections, suggesting that infection may trigger the initial inflammatory response in AOSD. Many viruses, including adenovirus, coxsackievirus, Epstein-Barr virus, echovirus 7, severe acute respiratory syndrome coronavirus 2, and certain bacteria are associated with the disease. Environmental factors activate the innate immune system; subsequently, the pattern-recognition receptors (PRRs) on immune cells interact with pathogen-associated molecular patterns (PAMPs). PAMPs include viral single-stranded DNA or RNA or bacterial components such as lipopolysaccharides (LPS) in gram-negative bacteria. The association of damage-associated molecular patterns (DAMPs), that occur after various inflammations, with the pathogenesis of AOSD has also been reported. Elevated levels of high mobility group box 1 (HMGB1), S100 protein, and histones have been reported in the sera of patients with acute AOSD.

Several PRR families, including C-type lectin receptors, Toll-like receptors (TLRs), and nucleotide-binding oligomerization domain receptors (NOD-like receptors, NLRs), recognize PAMPs and DAMPs in several infectious and inflammatory diseases. TLRs are type I transmembrane proteins located in intracellular endosomes, plasma membranes, or both. TLRs interact and respond to danger signals through intracellular signalling pathways and sense PAMPs and DAMPs in non-immune and immune cells. TLRs transmit signals through specific sets of adaptors and transcription factors and trigger various cellular responses, resulting in the increased expression of proinflammatory cytokines, such as IL-1β, IL-6, and IL-18.
expression of inflammatory factors, such as type I interferon (IFN), chemokines, IL-1, and IL-6\textsuperscript{18, 20}. TLR-mediated inflammation is implicated in the pathogenesis of sterile inflammations, such as wound healing, autoimmune or autoinflammatory diseases, and malignancies\textsuperscript{20, 21}. Especially, TLR1, TLR2, TLR4, TLR7 and TLR9 have been evaluated in several rheumatic diseases and their putative pathological roles were shown\textsuperscript{20}. Altered TLR ligands have also been implicated in the pathogenesis of AOSD, especially TLR4 and its ligands, such as S100 proteins and HMGB1\textsuperscript{15, 16, 22}. The expression of TLR7 on circulating precursors of myeloid dendritic cells (pre-mDCs) and mDCs considerably increased in patients with AOSD compared to that of healthy controls (HCs); TLR7 transcription levels correlated with the serum IL-1 and IFN-α levels in AOSD\textsuperscript{23}. However, there are limited data regarding the association of TLRs with the manifestations of AOSD in patients; the available data focus on TLR4 and TLR7\textsuperscript{22, 23}. To the best of our knowledge, the expression of TLR1, TLR2, and TLR9 in patients with AOSD has not yet been evaluated.

Therefore, we investigated the potential role of TLR1, TLR2, TLR4, TLR7, and TLR9 in the pathogenesis of AOSD, and their levels were quantified in the peripheral blood of patients with AOSD and HCs using flow cytometry. Furthermore, we used immunohistochemistry to detect the expression of these markers and evaluated their levels in the skin and lymph nodes (LN) of patients with AOSD compared with those of other skin diseases.

## Results

### Clinical characteristics of the patients

Table 1 shows the clinical characteristics of the 20 patients with AOSD and 15 HCs. There was no significant difference in the age or sex of patients with AOSD and HCs. Nine were in the initial stages before treatment, and the disease duration of the remaining 11 patients was 84.3 (29.8) months. Among the 11 patients, four discontinued their medications before the flare. Three patients were treated with methotrexate and intravenous tocilizumab, three patients were treated with methotrexate and leflunomide, and one patient was treated with azathioprine, at the time of sampling. There were no patients diagnosed with macrophage activation syndrome or fulminant hepatitis. The daily glucocorticosteroid dose of the seven patients with AOSD was 3.2 (1.2) mg prednisolone equivalent.

|                       | AOSD (n = 20) | HC (n = 15) | p-value |
|-----------------------|--------------|------------|---------|
| Age (years)           | 50.1 ± 13.6  | 43.2 ± 7.8 | 0.069   |
| Gender (F/M)          | 13/7         | 7/8        | 0.321   |
| Systemic manifestation | 15/5         |            |         |
| Chronic articular manifestation |            | 7/8        |         |
| Fever                 | 10 (50)      |            |         |
| Sore throat           | 4 (20)       |            |         |
| Skin rash             | 12 (60)      |            |         |
| Lymphadenopathy       | 3 (15)       |            |         |
| Splenomegaly          | 2 (10)       |            |         |
| Hepatomegaly          | 2 (10)       |            |         |
| Pericarditis          | 0 (0)        |            |         |
| Arthritis             | 6 (30)       |            |         |
| Hemoglobin, g/dL      | 12.7 ± 1.7   |            |         |
| Leukocytes, /µL       | 9.515 ± 4.570|            |         |
| Neutrophils, /µL      | 7.306 ± 4.447|            |         |
| Platelets, x 10¹²/µL  | 287.7 ± 137.0|            |         |
| Ferritin, ng/mL       | 2.137.6 ± 4.512.0| |         |
| ESR, mm/h             | 37.1 ± 31.8  |            |         |
| CRP, mg/dL            | 5.63 ± 9.06  |            |         |
| AST/ALT, mg/dL        | 39.7 ± 39.1/34.8 ± 27.4| |         |
| Bilirubin, mg/dL      | 0.55 ± 0.31  |            |         |
| Albumin, g/dL         | 4.2 ± 0.6    |            |         |
| Systemic score        | 2.5 ± 1.9    |            |         |
| IL-1β, pg/mL          | 1.86 ± 5.99  | 0.00 ± 0.00| 0.214   |
| IL-6, pg/mL           | 9.56 ± 15.1  | 0.00 ± 0.00| 0.012   |
| IL-18, ng/mL          | 7.47 ± 6.44  | 0.44 ± 0.34| < 0.001 |
| TNF-α, pg/mL          | 4.54 ± 7.65  | 0.42 ± 1.25| 0.086   |

Table 1. Clinical characteristics of patients. AOSD, adult-onset Still’s disease; HC, healthy control; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AST, aspartate transaminase; ALT, alanine transaminase; IL, interleukin; TNF, tumor necrosis factor. All values are presented as numbers (with percentages) or means ± standard deviations. The systemic scoring system of Pouchot et al.\textsuperscript{40} assigns a score from 0 to 12 with 1 point for each of the following manifestations: fever, typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly or abnormal liver function test data, splenomegaly, lymphadenopathy, leukocytosis $\geq$ 15,000/mm$^3$, sore throat, myalgia, and abdominal pain. These data were assessed using a Mann–Whitney U test or Fisher’s Exact test.
The IL-6 levels in AOSD patients [9.56 (15.1) pg/mL] were higher than those in HC [0.0 (0.0) pg/mL, \(p = 0.012\)]. Furthermore, the IL-18 levels in AOSD patients [7.47 (6.44) ng/mL] were higher than those in HC [0.44 (0.34) ng/mL, \(p < 0.001\)]. However, there was no statistically significant difference in the levels of IL-1β and TNF-α between AOSD patient and HCs, although those levels in AOSD were higher than those in HCs.

Microarray data in patients with AOSD and HCs. Microarray data analysis revealed significant changes in the expression of genes related to TLR signalling between the active and inactive AOSD groups, between active AOSD and HC, or between inactive AOSD and HC (adjusted \(p\)-value from LIMMA test < 0.05). Among the DE genes, 60 were upregulated, and 34 were downregulated. Ten genes were also found to be differentially expressed (adjusted \(p\)-values < 0.05) in active AOSD compared to HC. The lists of significant DE genes (in active AOSD vs. HC, inactive AOSD vs. HC, and active vs. inactive AOSD) were compared using Venn diagrams (Table S1). In particular, the expression levels of TLR1, TLR2, TLR4, TLR7, and TLR9 genes in active AOSD relative to the HC or inactive AOSD are shown as a heatmap (Fig. 1). The expression levels of TLR1, TLR2, and TLR4 in active AOSD or inactive AOSD were increased in comparison to those of the HC. However, the expression levels of TLR7 and TLR9 in active AOSD or inactive AOSD were not different to those of the HC. The expression levels of TLR1 and TLR7 in active AOSD were increased than those of inactive AOSD.

The intensity of cells presenting TLR1, TLR2, TLR4, TLR7, and TLR9 in patients with AOSD and HCs. Representative examples of flow cytometric histograms of cells presenting several TLR markers from the peripheral blood of one patient with AOSD and an HC are shown in Fig. 2. Significantly higher mean intensity of cells presenting TLR2 from whole blood was observed in patients with AOSD [1.27 (0.43)] than in HC [0.98 (0.04), \(p < 0.001\)]. A significantly higher intensity of cells presenting TLR7 from whole blood was seen in patients with AOSD [1.28 (0.29)] than in HC [1.06 (0.86), \(p = 0.006\)]. However, there was no significant difference in the...
intensity of cells presenting TLR1, TLR2, TLR4, TLR7, or TLR9 between patients with systemic and chronic articular AOSD. Furthermore, there was no significant difference in the intensity of cells presenting TLR1, TLR2, TLR4, TLR7, or TLR9 between patients with active (n = 13) and inactive AOSD (n = 7).

The intensity of stained cells presenting TLR1, TLR2, TLR4, TLR7, and TLR9 according to the levels of disease activity markers or clinical manifestations in patients with AOSD. Correlations between the levels of disease activity markers and the intensity of stained cells presenting several TLR markers in patients with AOSD are shown in Table 2. TLR1 intensities correlated with lactate dehydrogenase (LDH) and ferritin levels. TLR2 intensities from whole cells positively correlated with systemic score and LDH and ferritin levels. TLR9 intensities also correlated with LDH and ferritin levels. However, there were no correlations between neutrophil counts and several TLR markers in patients with AOSD. TLR2 intensities from whole cells correlated with serum levels of IL-1β, IL-6, and IL-18. TLR4 intensities positively correlated with IL-1β, and TLR7 intensities correlated with IL-18.

We evaluated the correlation between each cell TLR marker and the remaining four TLR markers considered in this study in patients with AOSD. The intensities of each TLR marker in peripheral blood mononuclear cells (PBMCs) positively correlated with the intensities of the rest of the four TLR markers being studied (p < 0.001).
CXCR3, TLR9 staining positively correlated with inflammatory cells stained for CXCL11 and CXCL12. AOSD. The expression of TLR4 correlated significantly with inflammatory cells stained for CD4, CXCL11, and expression of TLR2 correlated significantly with CXCL10-stained inflammatory cells in the skin of patients with 

Table 2. Correlation between each Toll-like receptor (TLR) level and levels of disease activity markers in adult onset Still's disease. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; LDH, lactate dehydrogenase; AST, aspartate transaminase; ALT, alanine transaminase; IL, interleukin; TNF, tumor necrosis factor. Spearman's correlation coefficients were calculated. The systemic scoring system of Pouchot et al. assigns a score from 0 to 12 with 1 point for each of the following manifestations: fever, typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly or abnormal liver function test data, splenomegaly, lymphadenopathy, leukocytosis ≥ 15,000/mm³, sore throat, myalgia, and abdominal pain. These data were assessed using a Spearman's correlation test.

When the cell TLR marker was analysed with regard to the manifestations of AOSD, the patient who had arthritis [1.34 (0.18)] provided a higher TLR2 intensity than the patient who did not have arthritis [1.24 (0.5), p = 0.02], and the patient who had hepatosplenomegaly [1.59 (0.04)] had a higher intensity of TLR7 than those who did not have hepatosplenomegaly [1.25 (0.29), p = 0.042] (Table 3).

Immunohistochemical data of the skin lesions of 32 patients with AOSD and those with eczema, psoriasis, and HC. As a control for TLR1, TLR2, TLR4, TLR7, and TLR9 immunohistochemical (IHC) evaluation, we stained lymphoid cells in the paracortical zone or germinal centre of a reactive tonsil. This analysis revealed a granular pattern of cytoplasmic staining. The staining patterns of inflammatory cells in skin biopsies were similar to those of lymphoid cells in the tonsils. The mean percentages of inflammatory cells expressing TLR1, TLR2, TLR4, TLR7, and TLR9 in skin lesions from patients with AOSD, eczema, and psoriasis and the skin from HCs are summarized in Table 4 and Fig. 3. The comparative analysis shows that the percentage of inflammatory cells expressing TLR2 in skin lesions from patients with AOSD was significantly greater than that in HCs (p = 0.002). The percentage of inflammatory cells expressing TLR1 was significantly greater than that in HC (p = 0.001) and patients with eczema (p = 0.041) or psoriasis (p = 0.001). We evaluated the correlations between the percentages of inflammatory cells staining for the TLRs and inflammatory cell grades or percentages, such as CD4, CD8, CD68, C-X-C motif chemokine 9 (CXCL9), CXCL10, CXCL11, CXCL12, C-X-C chemokine receptor type 3 (CXCR3), and CXCR4 (Table S2). The expression of TLR2 correlated significantly with CXCL10-stained inflammatory cells in the skin of patients with AOSD. The expression of TLR4 correlated significantly with inflammatory cells stained for CD4, CXCL11, and CXCR3. TLR9 staining positively correlated with inflammatory cells stained for CXCL11 and CXCL12.

Immunohistochemical data for LNs. The IHC findings for TLR1, TLR2, TLR4, TLR7, and TLR9 of LNs are shown in Table 5 and Fig. 4. The table summarizes the mean percentages of inflammatory cells expressing TLR1, TLR2, TLR4, TLR7, and TLR9 in LNs from patients with AOSD, tuberculosis (Tb) lymphadenitis, T cell lymphoma, histiocytic necrotizing lymphadenitis (HN), and reactive LNs. The comparative analysis shows that the percentage of inflammatory cells expressing TLR1 in LNs from patients with AOSD was significantly greater than that in patients with TB lymphadenitis (p = 0.029), T cell lymphoma (p = 0.004), and reactive LN (p = 0.004).

| Disease activity markers | Correlation coefficient, r (p-value) |
|-------------------------|-------------------------------------|
|                         | TLR1      | TLR2      | TLR4      | TLR7      | TLR9      |
| Systemic score          | 0.440 (0.052) | 0.446 (0.049) | 0.178 (0.452) | −0.057 (0.811) | 0.379 (0.099) |
| Leukocyte               | −0.200 (0.397) | −0.261 (0.265) | −0.342 (0.140) | −0.265 (0.260) | −0.286 (0.222) |
| Neutrophil              | −0.280 (0.232) | −0.247 (0.295) | −0.349 (0.132) | −0.211 (0.373) | −0.195 (0.409) |
| Hemoglobin              | −0.178 (0.453) | −0.294 (0.208) | 0.001 (0.996) | 0.091 (0.704) | −0.185 (0.435) |
| Platelet                | −0.027 (0.911) | −0.079 (0.741) | 0.026 (0.914) | 0.140 (0.556) | −0.180 (0.448) |
| ESR                     | −0.058 (0.807) | −0.013 (0.957) | −0.194 (0.413) | −0.194 (0.414) | −0.107 (0.653) |
| CRP                     | −0.015 (0.950) | −0.052 (0.827) | −0.138 (0.562) | −0.172 (0.468) | −0.056 (0.814) |
| Ferritin                | 0.804 (<0.001) | 0.829 (<0.001) | 0.547 (0.015) | 0.141 (0.533) | 0.798 (<0.001) |
| LDH                     | 0.716 (<0.001) | 0.728 (<0.001) | 0.465 (0.039) | 0.203 (0.391) | 0.686 (0.001) |
| Albumin                 | −0.096 (0.688) | −0.140 (0.557) | 0.142 (0.549) | 0.232 (0.324) | −0.079 (0.740) |
| Bilirubin               | 0.029 (0.903) | −0.049 (0.839) | 0.038 (0.874) | 0.060 (0.801) | 0.056 (0.816) |
| AST                     | −0.071 (0.765) | −0.072 (0.762) | −0.273 (0.244) | −0.374 (0.104) | −0.164 (0.491) |
| ALT                     | −0.154 (0.516) | −0.260 (0.269) | −0.297 (0.204) | −0.245 (0.298) | −0.299 (0.200) |
| IL-1β                   | 0.309 (0.071) | 0.380 (0.025) | 0.387 (0.022) | 0.070 (0.689) | 0.148 (0.395) |
| IL-6                    | 0.140 (0.422) | 0.474 (0.004) | 0.126 (0.470) | 0.267 (0.121) | 0.180 (0.301) |
| IL-18                   | 0.174 (0.317) | 0.606 (<0.001) | 0.112 (0.523) | 0.385 (0.022) | 0.213 (0.219) |
| TNF-α                   | 0.130 (0.457) | 0.318 (0.063) | −0.028 (0.875) | 0.070 (0.689) | −0.023 (0.895) |
| TLR1                    | 0.928 (<0.001) | 0.806 (<0.001) | 0.584 (<0.001) | 0.905 (<0.001) | 0.905 (<0.001) |
| TLR2                    | 0.928 (<0.001) | 0.838 (<0.001) | 0.588 (<0.001) | 0.932 (<0.001) | 0.932 (<0.001) |
| TLR4                    | 0.806 (<0.001) | 0.838 (<0.001) | 0.669 (<0.001) | 0.813 (<0.001) | 0.813 (<0.001) |
| TLR7                    | 0.584 (<0.001) | 0.588 (<0.001) | 0.669 (<0.001) | 0.614 (<0.001) | 0.614 (<0.001) |

**Table 2.** Correlation between each Toll-like receptor (TLR) level and levels of disease activity markers in adult onset Still’s disease. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; LDH, lactate dehydrogenase; AST, aspartate transaminase; ALT, alanine transaminase; IL, interleukin; TNF, tumor necrosis factor. Spearman’s correlation coefficients were calculated. The systemic scoring system of Pouchot et al. assigns a score from 0 to 12 with 1 point for each of the following manifestations: fever, typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly or abnormal liver function test data, splenomegaly, lymphadenopathy, leukocytosis ≥ 15,000/mm³, sore throat, myalgia, and abdominal pain. These data were assessed using a Spearman’s correlation test.
The percentage of inflammatory cells expressing TLR2 was greater than that in HNL (p = 0.042). Furthermore, the percentage of inflammatory cells expressing TLR4, TLR7, and TLR9 in LNs from patients with AOSD was significantly greater than that in patients with T cell lymphoma (p = 0.001) and reactive LNs (p = 0.012).

**Discussion**

Patients with AOSD showed significantly higher intensities of cells presenting TLR2 and TLR7 from whole blood than HCs. In particular, the TLR2 intensities from whole blood cells correlated with serum inflammatory cytokine levels and several disease activity markers, such as systemic score, LDH, and ferritin. Furthermore, the intensity of each TLR correlated with that of other TLRs. The expression of TLR2-positive inflammatory cells was higher in skin biopsy samples from patients with AOSD than in HCs. TLR9-expressing positive inflammatory cell counts were higher in skin lesions from patients with AOSD than in HC, eczema, and psoriasis groups. The expression levels of TLR1, TLR4, TLR7, and TLR9 were higher in LNs of patients with AOSD than in LNs of those with T cell lymphoma and reactive lymphadenopathy.

The role of the innate immune system has been investigated in the initiation and progression of several autoimmune or inflammatory diseases. In particular, TLR-mediated inflammation is implicated in several rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis. TLR2, TLR3, TLR4, and TLR7 were overexpressed in the macrophages of synovial tissues, and the levels of TLR2 and TLR4 expression were correlated with IL-12 and IL-18 levels in the synovial tissue of patients with RA. TLR7 was highly expressed in mouse models of severe lupus and in patients with SLE, and inhibition of TLR7 signalling ameliorated inflammation of the lungs and kidneys in lupus-prone mice. Several TLR ligands as DAMPs were evaluated in the serum of patients with active AOSD; serum S100A8/A9, S100A12, HMGB1, and amyloid A levels increased in patients with active AOSD. However, few studies have evaluated TLR in the PBMCs of patients with AOSD. Only one study evaluated the expression of TLR7 on circulating pre-mDCs and mDCs in patients with AOSD. The transcript levels of TLR7 and associated signalling molecules, including Myd88, TRAF6, and IFN-α, were correlated with the serum cytokine levels of IL-1β and IFN-α. The levels of NLRP3

| Manifestations | TLR2 | p-value | TLR7 | p-value |
|----------------|------|----------|------|----------|
| Fever          |      |          |      |          |
| (+), n = 10    | 1.31 ± 0.58 | 0.579   | 1.22 ± 0.23 | 0.353   |
| (−), n = 10    | 1.23 ± 0.19 |        | 1.34 ± 0.35 |        |
| Sore throat    |      |          |      |          |
| (+), n = 4     | 1.58 ± 0.92 | 0.892   | 1.42 ± 0.24 | 0.148   |
| (−), n = 16    | 1.19 ± 0.17 |        | 1.24 ± 0.30 |        |
| Skin rash      |      |          |      |          |
| (+), n = 12    | 1.29 ± 0.53 | 0.678   | 1.22 ± 0.22 | 0.305   |
| (−), n = 8     | 1.24 ± 0.21 |        | 1.37 ± 0.38 |        |

**Table 3.** Comparison of the intensities of Toll-like receptor2 (TLR2) and TLR7 expression according to disease manifestations in adult onset Still’s disease. These data were assessed using a Mann–Whitney U test.

| Staining cell percent | AOSD (n = 32) | p-value (AOSD vs. eczema) | Staining cell percent | AOSD (n = 32) | p-value (AOSD vs. psoriasis) | Staining cell percent | HC (n = 5) | p-value (AOSD vs. HC) |
|-----------------------|---------------|---------------------------|-----------------------|---------------|-------------------------------|-----------------------|------------|-----------------------|
| TLR1                  | 81.9 ± 8.2    | 70.0 ± 16.0               | 0.097                 | 72.0 ± 5.7    | 0.021                         | 70.0 ± 18.4           | 0.128      |                       |
| TLR2                  | 34.8 ± 24.1   | 27.0 ± 30.9               | 0.328                 | 27.2 ± 21.4   | 0.620                         | 6.2 ± 3.6             | 0.002      |                       |
| TLR4                  | 52.3 ± 29.8   | 75.0 ± 10.0               | 0.117                 | 64.0 ± 11.4   | 0.620                         | 77.0 ± 11.0           | 0.071      |                       |
| TLR7                  | 19.3 ± 15.7   | 24.4 ± 31.2               | 0.682                 | 11.0 ± 4.2    | 0.213                         | 9.6 ± 6.6             | 0.106      |                       |
| TLR9                  | 40.2 ± 27.9   | 17.6 ± 20.2               | 0.041                 | 7.4 ± 9.9     | 0.001                         | 5.4 ± 4.5             | 0.001      |                       |

**Table 4.** Toll-like receptor (TLR) immunostaining results in skin biopsies from patients with adult-onset Still’ disease (AOSD), eczema, and psoriasis and healthy controls (HC). p-values determined using a Mann–Whitney U-test. AOSD, adult-onset Still’s disease; HC, healthy control.
**Figure 3.** Toll-like receptor (TLR)1 (A–D), TLR2 (E–H), TLR4 (I–L), TLR7 (M–P), and TLR9 (Q–T) expression in skin biopsies of patients with adult-onset Still's disease (AOSD) (A,E,I,M,Q), eczema (B,F,J,N,R), psoriasis (C,G,K,O,S) and healthy controls (HCs) (D,H,L,P,T). Original magnification, ×100 or ×400. TLR2 was more frequently expressed in the skin of patients with AOSD than in that of HCs. TLR9 was more frequently expressed in the skin of patients with AOSD than in that of patients with eczema or psoriasis, and HCs.

| Staining cell | Staining cell | p-value (AOSD vs. Tb lymphadenitis) | p-value (AOSD vs. T cell lymphoma) | Staining cell | p-value (AOSD vs. HNL) | p-value (AOSD vs. reactive LN) |
|---------------|---------------|-----------------------------------|-----------------------------------|---------------|------------------------|------------------------------|
| TLR1          | 34.4 ± 17.9   | 13.2 ± 13.2                       | 0.029                             | 9.2 ± 6.2     | 0.004                  | 24.0 ± 2.9                   | 0.240                        |
| TLR2          | 17.3 ± 16.6   | 6.8 ± 5.7                         | 0.190                             | 20.0 ± 31.8   | 0.438                  | 4.8 ± 3.0                    | 0.042                        |
| TLR4          | 31.1 ± 13.6   | 44.0 ± 26.0                       | 0.364                             | 4.4 ± 3.4     | 0.001                  | 52.0 ± 17.5                  | 0.060                        |
| TLR7          | 27.2 ± 20.0   | 32.0 ± 4.5                        | 0.190                             | 8.2 ± 7.2     | 0.019                  | 49.0 ± 12.5                  | 0.060                        |
| TLR9          | 18.3 ± 9.7    | 11.2 ± 11.2                       | 0.147                             | 3.6 ± 4.0     | 0.002                  | 21.0 ± 19.2                  | 0.898                        |

**Table 5.** Toll-like receptor (TLR) immunostaining results in lymph node (LN) biopsies from patients with adult-onset Still's disease (AOSD) and other similar conditions. p-values determined using a Mann–Whitney U-test. AOSD, adult-onset Still's disease; Tb, tuberculosis; HNL, histiocytic necrotizing lymphadenitis; LN, lymph node.
inflammasomes and their by-products increased in patients with AOSD and correlated with disease activity.

Interestingly, the levels of NLRP3 inflammasome pathway components were upregulated by a TLR7 agonist in PBMCs of patients with AOSD but not in those of HCs. Our study showed that the TLR2 and TLR7 intensities of PBMCs in patients with AOSD were significantly higher than those in HCs. These results could be interpreted in the same context as previous data related to TLR7 in AOSD. Furthermore, TLR2 intensities correlated with the levels of several inflammatory cytokines and disease activity markers and systemic scores and were higher in patients with arthritis than in those without arthritis. These results strongly suggest that the expression of TLR2 on circulating mononuclear cells may play a significant role in the pathogenesis, clinical manifestation, and disease activity of AOSD. TLR2 is an extracellular receptor, and its signalling via MyD88 is triggered by endogenous DAMPs, such as heat shock protein, serum amyloid A, HMGB1, and β-defensin. The levels of these endogenous DAMPs are already elevated in the serum of patients with AOSD or systemic juvenile idiopathic arthritis; they could interact with TLR2 in circulating mononuclear cells. These interactions can aggravate inflammation in the pathogenesis of AOSD. Furthermore, Dectin-1 was found to physically interact and synergize with TLR2 to induce IL-1β and TNF-α in human PBMCs. A recent study evaluated the frequency of blood cells expressing Dectin-1 between AOSD and HC and showed that the frequency of granulocytes presenting Dectin-1 was increased in the active phase of AOSD compared to that in the inactive phase. However, our microarray results showed the expression levels of TLR1, TLR2, and TLR4, not TLR7 were increased in active AOSD compared to HCs. These discrepancies between microarray and FACS data could be explained by the difference between RNA and protein expression levels, and the difference enrolled patients characteristics.

We analysed the expression of several TLRs during the initial phase of AOSD, using skin and LN biopsy specimens obtained before treatment. The skin of patients with AOSD showed increased expression of TLR2.
and TLR9 compared to that in HCs. In particular, increased expression of TLR9 was observed in the skin lesions of patients with AOSD compared to that of HCs, eczema, and psoriasis groups. The expression of TLR2 correlated significantly with CXCL10-stained inflammatory cells in the skin of patients with AOSD. TLR9 staining positively correlated with inflammatory cells stained for CXCL11 and CXCL12. These results suggest that TLR2 and TLR9 induce chemokine production during skin inflammation in AOSD. TLR2 expression and some skin inflammatory diseases, such as atopic dermatitis and erythema nodosum lesions, were shown. One study showed that TLR2-mediated sensing of Staphylococcus aureus-derived signalling was strongly impaired in Langerhans cells from atopic dermatitis skin.53. On the other hand, the other study suggested that innate TLR2 signals convert transient T helper 2 cell-mediated dermatitis into persistent inflammation, as seen in chronic atopic dermatitis, through IL-4-mediated suppression of IL-10. TLR9 is well known as a receptor that responds to nucleic acids, and there have been several reports that showed association with skin lesions of autoimmune diseases. A recent study suggested that systemic sclerosis immune complexes have the potential pathogenicity mediated by TLR9 via the interaction with nucleic acid fragments on fibroblasts. Interestingly, highly expressed TLR in the lymphadenopathy of AOSD differed based on the specific lymphadenopathy. The expression levels of TLR1, TLR4, TLR7, and TLR9 increased in the LNs of patients with AOSD compared to that in reactive LN or T cell lymphoma. However, TLR2 expression increased in the LNs of patients with AOSD compared to that in HNL. Furthermore, the expression level of TLR1 was higher in the LNs of patients with AOSD than in Tb lymphadenopathy. One study analysed the expression of TLR1 to 9 using quantitative real-time PCR in frozen LN samples from patients with follicular lymphoma, diffuse large B-cell lymphoma, and peripheral T-cell lymphoma. TLR expression was highly variable among lymphoma subtypes; for example, TLR5 showed lower expression in follicular lymphoma, and TLR2 was overexpressed in both diffuse large B-cell lymphoma and peripheral T-cell lymphoma. In this study, we recruited LNs from patients with T-cell lymphoma for differential diagnosis of LNs in AOSD. The expression level of TLR2 was similar in LNs from patients with T cell lymphoma and AOSD; however, TLR1, TLR4, TLR7, and TLR9 expression levels were higher in the LNs of patients with AOSD than in T cell lymphoma. Therefore, immunohistochemical analysis of TLR expression in the LNs could be an additional marker for differentiating several diseases with similar clinical manifestations.

This study had some limitations. TLR markers were not compared with those of other febrile diseases as positive controls in terms of their diagnostic value, and the sample sizes were small for comparison of TLR expression between systemic and chronic articular manifestations of AOSD. There were no follow-up blood samples or skin or LN biopsies in AOSD for the comparison of TLR expression. The disease activities of the AOSD were relatively low with systemic score 2.5 ± 1.9, and could affect relatively low IL-1β and TNF-α levels in serum of the AOSD patients. However, we recruited the patients prospectively, observed several TLRs in AOSD and evaluated their roles in assessing disease activity and expression in the skin and LNs of patients with AOSD and compared their expression with TLR expression of several similar diseases. Based on this study, it is necessary to determine whether the symptoms of AOSD could be improved by regulating the TLR sub-signalling system in the future. Further studies including larger sample sizes with follow-up blood samples and control groups including other febrile disorders are required to assess the usefulness of TLR expression in patients with AOSD. Additionally, identifying other DAMPs and PAMPs that could stimulate TLR expression and TLR expressed cellular types and characteristics in AOSD would be helpful in understanding the pathogenesis and treatment of AOSD. This study targeted only TLR1, TLR2, TLR4, TLR7 and TLR9. Further studies are needed for the other TLRs in AOSD. In conclusion, we found significantly higher numbers of circulating TLR2-positive cells in patients with AOSD. Furthermore, numbers of circulating TLR2-positive cells were increased in patients with AOSD and arthritis compared to that in patients without arthritis. We confirmed the expression of these PRRs in skin rash tissue from patients with AOSD. These results suggest that TLR2 may play an important role in the systemic inflammatory process and arthritis in AOSD. Furthermore, immunohistochemical staining for TLRs in skin lesions and LNs may facilitate differentiating AOSD from other similar conditions.

Materials and methods

Subjects. A total of 20 patients with AOSD and 15 HCs were included in the study. Patients with AOSD were diagnosed according to Yamaguchi’s criteria; patients with infections, other autoimmune diseases, and malignancies were excluded. The HCs were individuals with no history of autoimmune, rheumatic, or other malignant diseases. PBMCs were isolated from the study participants. Fifteen of the 20 patients with AOSD with systemic inflammation were enrolled in the study. Among them, nine were in the initial stages of high-level disease activity before treatment. Six patients experienced a systemic flare-up of the disease during follow-up. The remaining five patients had chronic articular pattern disease. The medical histories and clinical characteristics, including those identified during the physical examination of all subjects, were collected after reviewing the subjects’ medical records and interviewing the subjects during sample collection. The complete blood count, erythrocyte sedimentation rate, C-reactive protein and ferritin levels, and liver function test results were reviewed. The disease activity of AOSD was assessed according to the widely accepted systemic scoring method. The inactive disease was defined as the absence of systemic symptoms such as fever, myalgia, skin rash, and pericarditis. This study was approved by the Institutional Review Board (IRB) of Ajou University Hospital (IRB No. AJIRB-BMR- OBS-19-053), and was conducted in compliance with the principles of the Declaration of Helsinki. Informed consent was obtained from all subjects.

Microarray data analysis. PBMCs of 2 active AOSD patients, 2 inactive AOSD patients, and 2 HCs were included in microarray data analysis. CEL files were imported into the Gene Expression Workflow in GeneSpring GX version 14.9.1 (Agilent Technologies Inc.). The RMA algorithm (background correction, log2 transformation, and probeset summarization) was performed using the default settings in the GeneSpring software.
The principal component analysis, which reduces the dimensionality of a dataset consisting of a large number of interrelated variables, was performed using a covariance dispersion matrix as part of the quality control of the data. Differential expression (DE) between exposed (treated) and unexposed (control) rats was predicted at the gene level (probesets summarized into transcript clusters/genes). Unpaired t-test was used to compare the individual gene expression data with respect to treated versus control groups. DE genes were defined based on an absolute fold change equal to or greater than 2.0 and a p-value ≤ 0.05. The input for the heatmap (TreeView Ver.1.1.6r4) was the log2-transformed intensities of DE genes with an absolute fold change equal to or greater than 2.0 and a p-value ≥ 0.05.

Flow cytometry of cells presenting TLR1, TLR2, TLR4, TLR7, and TLR9. Twenty patients with AOSD and 15 HC subjects were used for fluorescence-activated cell sorting (FACS) analysis. PBMCs were isolated using CPT™ Mononuclear Cell preparation tube-BD Vacutainer® (BD Biosciences, Franklin Lakes, NJ, USA). For anti-TLR7 and TLR9 intracellular antibody reactions, cells were pre-treated with Tween 20. Cells (1 × 10⁶) in each tube were incubated with FACS blocking buffer (3% BSA in PBS) at 4 °C for 1 h. After blocking, fluorescein isothiocyanate (FITC)-labelled anti-TLR1 (Abcam, Cambridge, MA, USA), anti-TLR2 (Abcam), anti-TLR7 (Thermo Fisher Scientific Inc., Waltham, MA, USA), and anti-TLR9 (Abcam) and phycoerythrin-labelled anti-TLR4 (Abcam) were added and incubated for 1 h at 4 °C. The same colour-labelled antibodies were applied separately to different tubes for isotype control. The stained cells were then washed with FACS buffer and analysed for 10,000 cells using a flow cytometer (FACS Aria III; Becton, Dickinson and Company, San Jose, CA, USA). The FACS data were based on specific markers and were used to analyse the gated populations. The density was plotted using FlowJo V.10 software (Becton, Dickinson and Company, Ashland, OR, USA).

Cytokine assay. Venous blood of the AOSD patients and HCs was extracted in serum separator tubes, containing an anticoagulant, EDTA, and aliquots of the blood were centrifuged for 10 min at 2500 rpm. After aspirating the serum, the samples were stored at − 20 °C. Serum IL-1β, IL-6, IL-18 and TNFα levels were measured using enzyme-linked immunosorbent assay kits (R&D Systems, Inc., Minneapolis, MN) according to the manufacturer’s protocol.

Histopathological evaluation of skin and lymph node specimens. Skin biopsy materials were retrospectively collected from 32 patients with active AOSD, between 2000 and 2019, for the evaluation of skin rashes. Informed consent was waived by the IRB because of the retrospective nature of the study. The haematoxylin and eosin (H&E) stained sections were independently reviewed by three pathologists to evaluate epidermal changes, including epidermal necrosis, vacuolization of basal keratinocytes, parakeratosis, the presence of macrophage infiltration, inflammatory cell infiltration, and karyorrhexis. We examined the H&E-stained sections of excisional LN biopsy samples obtained from nine patients with AOSD.

Immunohistochemical staining for TLRs in 32 skin and nine LN samples from patients with active AOSD. Formalin-fixed, paraffin-embedded sections were analysed by immunohistochemistry using a Benchmark XT automated staining system (Ventana Medical Systems Inc., Tucson, AZ, USA). The primary antibodies used were anti-TLR1 (1:500; Abcam), TLR2 (1:100 for LNs and 1:200 for skin; Abcam), TLR4 (1:400; Santa Cruz Biotechnology, Santa Cruz, CA, USA), TLR7 (1:100; Abcam), and TLR9 (1:400; Abcam). Staining was observed using the Ventana Optiview DAB kit (Ventana Medical Systems Inc., Oro Valley, AZ, USA). The IHC results for TLR1, TLR2, TLR4, TLR7, and TLR9 were graded according to the percentage of positive lymphoid cells and histiocytes.

Statistical analyses. Continuous variables were expressed as mean (standard deviation), and categorical variables were expressed as frequencies with percentages. The Mann–Whitney U test was used to compare TLR expression levels in PBMCs from patients with AOSD and HCs and in the skin and LNs from patients with AOSD and those with control diseases. We calculated Spearman correlations between TLR expression levels and systemic disease activity levels. All statistical analyses were performed using SPSS (version 23.0; SPSS, Chicago, IL, USA). P values < 0.05 indicated statistical significance.

Ethics declarations and approval for human experiments. The study was approved by the institutional review board of Ajou University Hospital (IRB No. AJIRB-BMR-OBS-19-053).

Consent to participate and consent to publish. All study participants provided informed consent.

Data availability. All available data are reported in the manuscript and supplementary file.

Received: 8 November 2021; Accepted: 31 May 2022
Published online: 17 June 2022

References
1. Ruscitti, P. & Giacomelli, R. Pathogenesis of adult onset Still's disease: current understanding and new insights. Expert. Rev. Clin. Immunol. 14, 965–976 (2018).
2. Kim, H. A., Am, J. M., Nam, J. Y., Jeon, J. Y. & Suh, C. H. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease. *Clin. Rheumatol.* 39, 1399–1406 (2012).
3. Inoue, N. et al. Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis. *Clin. Immunol.* 169, 8–13 (2016).
4. Bamidis, A. D. et al. First manifestation of adult-onset Still's disease after COVID-19. *Lancet Rheumatol.* 3, e319–e321 (2021).
5. Iia, J. et al. Cytomegalovirus infection may trigger adult-onset still's disease onset or relapses. *Front. Immunol.* 10, 898 (2019).
6. Kussela, E. et al. Serum Epstein-Barr virus DNA, detected by droplet digital PCR, correlates with disease activity in patients with rheumatoid arthritis. *Clin. Exp. Rheumatol.* 36, 778–784 (2018).
7. Chen, D. Y. et al. Human parvovirus B19 nonstructural protein NS1 activates NLRP3 inflammasome signaling in adult-onset Still's disease. *Mol. Med. Rep.* 17, 3364–3371 (2018).
8. Chen, D. Y. et al. Significant association of past parvovirus B19 infection with cytopenia in both adult-onset Still's disease and systemic lupus erythematosus patients. *Clin. Chim. Acta.* 413, 855–860 (2012).
9. Kishida, D. et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. *Mod. Rheumatol.* 21, 215–218 (2011).
10. Escudero, F. J., Len, O., Falcó, V., de Sevilla, T. F. & Sellas, A. Rubella infection in adult onset Still's disease. *Ann. Rheum. Dis.* 59, 490 (2000).
11. Castanet, J. et al. Adult Still's disease associated with hepatitis C virus infection. *J. Am. Acad. Dermatol.* 31, 807–808 (1994).
12. Roberts-Thomson, P. J. et al. Adult onset Still's disease or cosackie polyarthritis?. *N. Z. J. Med.* 16, 509–511 (1986).
13. Wouters, J. M., van der Veen, J., van de Putte, L. B. & de Rooij, D. J. Adult onset Still's disease and viral infections. *Ann. Rheum. Dis.* 47, 764–767 (1988).
14. Piccinini, A. M. & Midwood, K. S. DAMPening inflammation by modulating TLR signalling. *J. Autoimmun.* 84, 107886. https://doi.org/10.1016/j.jaut.2021.102597 (2021).
15. Casello, I. et al. IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases. *PLoS ONE* 9, e107886. https://doi.org/10.1371/journal.pone.0107886 (2014).
16. Kim, H. A. et al. TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still's Disease and their association with disease activity and clinical manifestations. *Int. J. Mol. Sci.* 17, 1342 (2016).
17. Chen, D. Y. et al. Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still's disease. *Arthritis Res. Ther.* 15, 1–2 (2013).
18. Radtke, T. R. et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-γ. *Arthritis Rheum.* 50, 3856–3865 (2004).
19. Clancy, F. L. et al. TLR expression profiles are a function of disease status in rheumatoid arthritis and experimental arthritis. *J. Autoimmun.* 118, 102597. https://doi.org/10.1016/j.jaut.2021.102597 (2021).
20. Pawar, R. D. et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. *J. Am. Soc. Nephrol.* 18, 1721–1731 (2007).
21. Pascho, G. V. et al. Expression of TLR7, MyD88, NF-κB, and INF-α in B lymphocytes of mayan women with systemic lupus erythematosus in Mexico. *Front. Immunol.* 7, 22. https://doi.org/10.3389/fimmu.2016.00022 (2016).
22. Hasel, C. W. et al. Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset Still's disease. *J. Rheumatol.* 44, 1142–1150 (2017).
23. Cantarini, L. et al. Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis. *Yonsei Med. J.* 53, 1045–1048 (2012).
24. Fiererda, G., Meyer-Wentrup, F., Kullberg, B. J., Netea, M. G. & Adema, G. J. Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. *Cell Microbiol.* 10, 2058–2066 (2008).
25. Kim, H. A. et al. Highly expression of CD11b and CD32 on peripheral blood mononuclear cells from patients with adult-onset Still's disease. *Int. J. Mol. Sci.* 18, 202. https://doi.org/10.3390/ijms18010202 (2017).
26. Antunes, D. E. et al. Differential expression of IFN-γ, IL-10, TLR1, and TLR2 and their potential effects on downregulating leprosy reaction and erythema nodosum leprosum. *J. Immunol. Res.* 2019, 3405103 (2019).
27. Iwamoto, K. et al. Langerhans and inflammatory dendritic epidermal cells in atopic dermatitis aretolerized toward TLR2 activation. *Allergy* 73, 2205–2213 (2018).
28. Ozu, E. et al. Comparison of TLR-2, TLR-4, and antimicrobial peptide levels in different lesions of acne vulgaris. *Cutan. Ocul. Toxicol.* 35, 300–309 (2016).
29. Kaesler, S. et al. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10. *J. Allergy Clin. Immunol.* 134, 92–99 (2014).
30. Guiducci, C. et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nuclear acids via TLR7 and TLR9. *J. Exp. Med.* 207, 2931–2942 (2010).
31. Raschi, E. et al. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. *Arthritis Res. Ther.* 22, 265 (2020).
32. Kivits, E. et al. Immune complexes containing scleroderma-specific autoantibodies induce a proinflammatory phenotype in skin fibroblasts. *Arthritis Res. Ther.* 20, 187 (2018).
33. Smith, T. J. et al. Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. *Exp. Mol. Pathol.* 89, 284–290 (2010).
34. Pouchot, J. et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. *Medicine* 70, 118–136 (1991).

**Acknowledgements**

Thank you for English editing to Editage (Editage. co. kr).
Author contributions
J.H.H., M.H.A., J.Y.J., J.W.K., C.H.S., K.J.E., H.Y., and H.A.K. contributed to the study design and data collection, analysis, and interpretation. J.H.H., M.H.A., and H.A.K. contributed to the data collection and/or data interpretation. All authors revised the manuscript and gave final approval for submission.

Funding
This work was supported by grants from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science, and Technology [grant number 2019R1A2C1005988].

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-14004-4.

Correspondence and requests for materials should be addressed to H.-A.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected publication 2022